Today, the major therapeutic interventions for atherosclerotic coronary disease are percutaneous transluminal coronary angioplasty and coronary bypass graft surgery (see chapter by F. Loop, this volume). At the time of these therapeutic interventions, however, the disease has already become clinically ...
Severe atherosclerotic aortoiliac occlusive disease in a young HIV-infected patientepidemiologyhepatitis B virushepatitis C virusinjection drug useUnited Statesviral suppressionA 39-year-old white man with CDC stage C3 HIV infection who had been diagnosed at 23 years of age presented with complaints ...
A large and convincing body of evidence links increased coronary risk with both elevated plasma levels of low density lipoprotein (LDL) cholesterol and fibrinogen. Cholesterol in atherosclerotic lesions originates from cholesterol circulating in the bloo
Revascularization treatment recommendations based on atherosclerotic disease distribution: coronary artery bypass grafting versus stenting. In patients who have left main involvement, diffuse disease with severe atherosclerosis, diabetes mellitus, advanced age, or left ventricular dysfunction, the... KIDL Cruz...
Objective To summarize the experiences with Wingspan stent in the treatment of severe symptomatic atherosclerotic stenosis of the vertebrobasilar artery.Methods Clinical data of 30 patients with 31 severe symptomatic atherosclerotic stenoses in the vertebrobasilar artery were analyzed retrospectively.All the...
From 1976 to 1981, 22 patients were treated for atherosclerotic renovascular disease and with widespread atherosclerosis. The average age was 56 years. Preoperatively, the average blood pressure (BP) was 211/123 mm Hg. The standard operation was aortorenal bypass, associated with resection of an ...
Homozygous FH with an estimated prevalence of one in a million is associated with severe hypercholesterolemia with accelerated atherosclerotic CHD in childhood and without treatment, death usually occurs before the age of 30 years. Current approaches for the treatment of homozygous FH include statin-...
(CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Pati...
Background Implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) reduce mortality in patients with heart failure (HF) and left ventricular dysfunction. However, their efficacy in patients with chronic kidney disease (CKD) is controversial.Objective We examined the assoc...
Elevated levels of fibrinogen, a common phenomenon in hypercholesterolemia increases the viscosity of the blood and thereby further alters perfusion of tissues in severe atherosclerotic disease. Furthermore, fibrinogen and its degradation products can both influence prostaglandin metabolism by inhibiting PGI ...